<DOC>
	<DOCNO>NCT00514358</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics fluconazole infant evaluate dose exposure relationship current fluconazole dosing infant receive fluconazole prevention treatment systemic fungal infection .</brief_summary>
	<brief_title>Fluconazole Pharmacokinetics Infants</brief_title>
	<detailed_description>Systemic fungal infection neonate associate high morbidity mortality . The increase use intravenous central catheter , parenteral nutrition , antibiotic neonatal intensive care unit contribute improved survival also increase incidence fungal sepsis particularly preterm infant . Decreasing fungal colonization decrease risk systemic fungal infection . Fluconazole potent antifungal agent triazole family . Fluconazole show reduce risk fungal colonization systemic infection however sufficient pharmacokinetic information neonate support dose guideline . In study , perform population pharmacokinetic study neonate receive fluconazole standard care . Fluconazole level measure use liquid chromatography/tandem mass spectroscopy ( LC/MS/MS ) assay small quantity blood appropriate neonate . Pharmacokinetic data obtain study support appropriate dosing fluconazole neonates provide information regard drug metabolism neonate .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>1 . Infant bear &gt; 23 week gestational age postnatal age &lt; 120 day 2 . Due receive fluconazole therapy clinical care 3 . Permission attend neonatologist 4 . Informed consent parent legal guardian</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>119 Days</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Fungal</keyword>
	<keyword>Infection</keyword>
	<keyword>sepsis</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>